QC (glutaminyl cyclase) catalyses the formation of N-terminal pGlu (pyroglutamate) in peptides and proteins. pGlu formation in chemoattractants may participate in the regulation of macrophage activation and migration. However, a clear molecular mechanism for the regulation is lacking. The present study examines the role of QC-mediated pGlu formation on MCPs (monocyte chemoattractant proteins) in inflammation. We demonstrated in vitro the pGlu formation on MCPs by QC using MS. A potent QC inhibitor, PBD150, significantly reduced the N-terminal uncyclized-MCP-stimulated monocyte migration, whereas pGlucontaining MCP-induced cell migration was unaffected. QC small interfering RNA revealed a similar inhibitory effect. Lastly, we demonstrated that inhibiting QC can attenuate cell migration by lipopolysaccharide. These results strongly suggest that QCcatalysed N-terminal pGlu formation of MCPs is required for monocyte migration and provide new insights into the role of QC in the inflammation process. Our results also suggest that QC could be a drug target for some inflammatory disorders.
INTRODUCTION
QC (glutaminyl cyclase, EC 2.3.2.5) has been reported to be responsible for the conversion of numerous N-terminal glutaminyl peptides into pyroglutamyl peptides [1] [2] [3] [4] . The formation of pGlu (pyroglutamate) at the N-terminus of numerous bioactive peptides, hormones and chemokines, such as thyrotropinreleasing hormone and MCPs (monocyte chemoattractant proteins), is believed to protect the peptides or proteins from exopeptidase degradation and/or to endow them with a proper conformation for binding to their receptors [5, 6] .
Two types of glutaminyl cyclase have been identified in mammalian cells. The first one possesses an N-terminal secretion signal, and is thus believed to be an sQC (secretory QC); the second carries an N-terminal anchorage signal and has been demonstrated to be an isoQC (Golgi-resident QC) in human cells [7] . These two QCs share ∼ 45 % sequence identity and similar catalytic characteristics [7] . Previous studies indicated that the enzymatic activity of isoQC is ∼ 3-fold weaker on several synthetic substrates than the activity of sQC [8] . A tissue distribution analysis revealed that the expression of isoQC is ubiquitous [7] , whereas sQC expression is higher in neuronal tissues and in several peripheral blood lymphocytes [1] .
Bacterial LPS (lipopolysaccharide)-activated monocytes produce and release various cytokines and chemokines, such as MCPs, in response to inflammatory stimulation. An earlier report indicated that LPS can induce QC activity in cultured macrophage cells [9] . However, the detailed molecular mechanism underlying the involvement of QC in monocyte activation and migration is lacking. QC is known to be involved in several pathological processes, such as amyloidotic diseases, osteoporosis, rheumatoid arthritis and melanoma [10] [11] [12] [13] . A number of papers have described that QC can catalyse N-terminal pGlu formation in several amyloid-β peptides [14, 15] , which in turn enhances the hydrophobicity and proteolytic resistance of the peptides, thus accelerating their aggregation and the progression of amyloidotic disorders [11, 16] . Increased gene expression of QC was reported in the peripheral blood monocytes from patients with rheumatoid arthritis [13] . The increased QC activity in monocytes presumably promotes the maturation of some pGlu-modified chemokines, which may consequently enhance the activation and migration of monocytes and accelerate the progression of the inflammatory disease. Therefore intervening in QC activity in monocytes may represent a strategy for the development of potential treatment paradigms.
On the other hand, a number of imidazole derivatives have been developed as potent QC inhibitors through their tight binding to the active-site Zn 2+ ion [17] . PBD150 is such a potent inhibitor with a K i value of ∼ 60 nM [18] . This inhibitor blocks QC activity effectively in cultured cells and transgenic mice [11, 19] . Oral application of PBD150 in an Alzheimer's disease mouse model reduced the formation of pGlu-modified amyloid-β peptides in brains and diminished amyloid plaque formation and gliosis [11] . Furthermore, our recent X-ray crystallographic works have revealed the subtle binding features of this QC inhibitor in the active sites of sQC and isoQC [8] . These studies strongly suggest that PBD150 is a useful and effective tool for studying the physiological and pathological roles of QC in human homoeostasis and diseases.
MCPs are members of the CC (Cys-Cys) chemokine family, which play a crucial role in the recruitment and activation of leucocytes during inflammation processes, allergic reactions Abbreviations used: CCL, chemokine (CC motif) ligand; CCR2, chemokine (CC motif) receptor 2; CI, chemotactic index; FU, fluorescent units; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; Gln-βNA, L-glutaminyl-2-naphthylamide; IFNγ, interferon γ; IL, interleukin; LPS, lipopolysaccharide; LTA, lipoteichoic acid; MCP, monocyte chemoattractant protein; βNA, 2-naphthylamine; nanoESI-MS, nanoelectrospray ionization-MS; PBDM, peripheral blood-derived monocyte; pGlu, pyroglutamate; pMCP, pyroglutamate-containing MCP; preMCP, N-terminal uncyclized MCP precursor; QC, glutaminyl cyclase; isoQC, Golgi-resident QC; QPCT, glutaminyl-peptide cyclotransferase; QPCTL, glutaminyl-peptide cyclotransferase-like; RT, reverse transcription; siRNA, small interfering RNA; sQC, secretory QC; TNF-α, tumour necrosis factor-α. 1 Correspondence may be addressed to either of these authors (email yml6120@gate.sinica.edu.tw or ahjwang@gate.sinica.edu.tw).
and tumour pathogenesis [20, 21] . Human CC chemokines are composed of four MCP isoforms, i.e. MCP-1/CCL2 [chemokine (CC motif) ligand 2], MCP-2/CCL8, MCP-3/CCL7 and MCP-4/CCL13, which share 60-70 % sequence homology [20, 22] . Some papers have reported that the N-terminal pGlu residue of MCPs is essential for their receptor binding and biological activities [6, 23] . This finding was further supported by the significantly reduced chemotactic activities of MCPs bearing mutations or truncations at their N-terminus [23] [24] [25] . To date, although the role of pGlu modification on these CC chemokine isoforms is evident, the relevant enzyme involved is not clearly defined.
In the present study, we examined the role of QC in MCPinduced monocyte migration. Using tandem MS analysis, we demonstrated that QC can catalyse the N-terminal pGlu formation on MCPs. We further showed that both PBD150 and siRNA (small interfering RNA) are able to reduce the chemotactic activity of monocytes and also inhibit the MCP-induced cell migration after LPS stimulation. Our results suggest that QC is a viable drug target for the treatment of some inflammatory disorders.
EXPERIMENTAL

Cell culture and treatment
U937 cells were purchased from the A.T.C.C. PBDMs (peripheral blood-derived monocytes) were separated from fresh whole blood collected from healthy volunteers using a FicollPaque Plus density gradient (GE Healthcare). [All donors gave full written informed consent, which was approved by the human subject research ethics committee of the IRB (Institutional Review Board) at Academia Sinica, Taiwan (IRB numbers AS-IRB01-10062 and AS-IRB01-11101)]. Cells were grown at (2-3)× 10 6 cells/ml in RPMI 1640 medium (Gibco) supplemented with 10 % (v/v) heat-inactivated FBS (fetal bovine serum; Gibco). Approximately 1×10 7 U937 cells or 1×10 6 PBDMs were treated with Escherichia coli LPS (O111:B4), LTA (lipoteichoic acid; Sigma) or IFNγ (interferon γ ) (PeproTech). Supernatant (conditioned medium) was harvested for transmigration assays. PBD150 was synthesized chemically as described previously [17] . PBDMs or U937 cells were pretreated with PBD150 for 2 h, followed by treatment with LPS or other stimulants as indicated in the Figures. Supernatants (conditioned medium) were harvested for migration assays.
Cell migration assay
Fresh U937 cells or PBDMs were incubated with 10 μM Calcein AM (acetoxymethyl ester; BD Biosciences) in culture for 1 h at 37
• C with 5 % humidified CO 2 . After that an aliquot of U937 cells (1×10 6 /ml) or PBDMs (1×10 5 /ml) cultured in serum-free RPMI 1640 medium was added to the upper compartment. We used 24-well BD Falcon TM HTS FluoroBlok Inserts (BD Biosciences). They have a PET [poly(ethylene terephthalate)] membrane (8 μm pore size) that blocks light transmission from 490 to 700 nm. This allows detection of cells present in the lower compartment only. The cells were allowed to migrate into the lower compartment in the presence of MCPs or conditioned medium, as detailed in the legend to each Figure, Fresh U937 cells were pretreated with CCR2 [chemokine (CC motif) receptor 2]-neutralizing antibody (E68, Abcam) or isotype antibody (3D3, Abcam) at 37
• C for 4 h. After washing three times with PBS, cells were loaded into the upper compartment for the migration assay.
Enzymatic activity
PBDMs or U937 cells were treated with LPS and/or PBD150 for 48 h. Cells were washed twice with ice-cold PBS and incubated in cell extraction buffer (Biosource) at 4
• C for 30 min, and cell extracts were cleaned by centrifugation. For preparing culture medium, the cell culture was centrifuged at 200 g for 5 min to remove cells and cell debris in the medium. The QC activity in cell extracts and culture medium was assayed using the fluorescent substrate Gln-βNA (L-glutaminyl-2-naphthylamide), as described previously [26] . Briefly, QC activities were evaluated at 25
• C using Gln-βNA. Reaction mixtures (100 μl) contained 1 mM fluorigenic substrate, excess human PAP I (pyroglutamyl aminopeptidase I) and an appropriately diluted aliquot (60 μl) of culture medium or cell extracts (with a total protein concentration of 300 μg/ml) in 50 mM Tris/HCl buffer, pH 8.0. During fluorescence measurements, excitation and emission wavelengths were set at 320 and 410 nm respectively. The reactions were initiated with the addition of culture medium or cell extract. Enzymatic activity was determined by the amount of βNA (2-naphthylamine) released, calculated using a standard curve for βNA under the same assay conditions. Measurements were taken using a Fluorolog-3 spectrofluorimeter (HORIBA Jobin Yvon).
Molecular modelling for the binding of MCPs to the active site of human QC
The initial model for MCP-1 bound to human QC was constructed on the basis of the crystal structure of a glutamine t-butyl esterbound human QC (PDB code 2AFU) and the structure of Pform MCP-1 (PDB code 1DOK). The model was optimized by energy minimization using the software CNS [27] . Models for other MCP-human QC complexes were generated on the basis of the MCP-1-human QC model and then were subjected to energy minimization using CNS. Finally, these models were verified with the software Profiles-3D [28] and were also checked with the software Procheck [29] . The structure Figures in the present paper were drawn with the program PyMOL (http://www.pymol.org/).
QC-dependent pGlu formation of MCPs
Recombinant human MCP-1 (CCL2), MCP-2 (CCL8), MCP-3 (CCL7) and MCP-4 (CCL13) were purchased from PeproTech. Recombinant human QC was produced as described previously [3] . For the QC-catalysed cyclization reaction, the 100 μl reaction mixtures contained 10 μl of each MCP (100 μg/ml), 0.2 μl of recombinant human QC (0.5 mg/ml) and 89.8 μl of sterile water. The reaction mixtures were incubated at room temperature (25 • C) for 2 h. N-terminal pGlu formation was then examined by nanoESI-MS (nano-electrospray ionization-MS) through a homemade nanosprayer applied with − 3.5 kV on the QSTAR-XL hybrid quadrupole time-of-flight mass spectrometer (Applied Biosystems/MDS Sciex). All data were acquired and processed using Analyst QS 1.1 with Bioanalyst 1.1 extension. The instrument was calibrated using fragment ions, resulting from CID (collision-induced dissociation) of Glu-fibrinopeptide B. Fullscan mass spectra were recorded in the positive-ion mode in the m/z range 400-2000, and the raw mass spectra were deconvoluted using Analyst QS 1.1 protein deconvolution software. The total MCPs [pMCPs (pyroglutamate-containing MCPs) and the remaining preMCPs (N-terminal uncyclized MCP precursors)] were isolated from the reaction mixture using an HPLC instrument equipped with a gel-filtration column (Shodex ® PROTEIN KW-802.5, 8 mm×300 mm; Showa Denko). The buffer used was 50 mM Tris/HCl, pH 8.0, and the flow rate was 0.5 ml/min.
ELISA
U937 cells (1×10 6 /ml) were seeded on to six-well culture plates and incubated for 48 h in a serum-free medium. The culture medium was collected by centrifugation, and the supernatant was stored at − 80
• C until use. The concentration of MCP-1, MCP-2, IL (interleukin)-8 and TNF-α (tumour necrosis factor-α) of the supernatant was measured with a monoclonal antibody against human MCP-1, MCP-2, IL-8 (RayBiotech) and TNF-α (BD Biosciences) using an ELISA kit according to the manufacturer's instructions. The mean value was obtained from triplicate measurements from three independent experiments. • C using 2× Power SYBR Green PCR Master Mix (Applied Biosystems) and 200 nM each of forward and reverse primers. Each assay was run on an Applied Biosystems 7300 RealTime PCR system in triplicate and fold changes in expression were derived using the comparative C T method. Levels of mRNA were normalized to GAPDH as an endogenous control.
Knockdown by QC siRNA sQC-specific siRNA (si-sQC-a, 5 -ATGATGTGCTGACGAGC-AGCATAGC-3 ; and si-sQC-1, 5 -GCTATGCTGCTCGTCA-GCACATCAT-3 ) and isoQC-specific siRNA (si-isoQC-1, 5 -GTCTCCTAATTGTGCTACAAT-3 ; and si-isoQC-2, 5 -CCTGCCTGATTTGAAACTCAA-3 ) were cloned into pLL3.7 with U6-GFP (green fluorescent protein) in the vector (Addgene). Plasmids were packed into lentiviral vector to infect U937 cells. GFP-positive cells were sorted to yield 95 % purity using a FACSAria Cell Sorter (BD Biosciences). Analysis of QC knockdown was conducted by Western blotting with mouse polyclonal anti-QPCT antibody (A01, Abnova; 1:1000) and mouse polyclonal anti-QPCTL antibody (B01P, Abnova; 1:2000) compared with GAPDH levels (mouse monoclonal antibody, Millipore; 1:5000).
Chemokine array
U937 cells were seeded on a six-well culture plate and treated with LPS and/or PBD150 for 48 h in a serum-free medium.
The culture medium was centrifuged, and the supernatant was collected and then stored at − 80
• C before use. The chemokine fluorescent antibody array was purchased from RayBiotech. The array contained quadruplicate antibody spots for 40 chemokines: MCP-2/CCL8, MCP-3/CCL7, MCP-4/CCL13, HCC-1/CCL14, HCC-4/CCL16, TARC/CCL17, PARC/CCL18, MIP-3β/CCL19, MIP-3α/CCL20, 6Ckine/CCL21, MDC/CCL22, MPIF-1/CCL23, TECK/CCL25, eotaxin-3/CCL26, CTACK/CCL27, CCL28, GRO/CXCL1, PF4/CXCL4, ENA-78/CXCL5, GCP-2/CXCL6, NAP-2/CXCL7, OPN/osteopontin, IP-10/CXCL10, I-TAC/CXCL11, SDF-1α/β/CXCL12, CXCL16, IL-9, IL-17F, IL-18Pa, IL-28A, IL-29, IL-31, LIGHT/TNFSF14, lymphotactin/XCL1, LIF, MIF, BTC, Axl/tyro7, TSLP and MSPα/MST1. The array slides were treated with the culture medium and then processed according to the manufacturer's instructions. Data acquisition and subsequent quantification were performed by employing a LuxScan 10K microarray scanner and the software LuxScan 3.0 (CapitalBio Corporation). Signal intensity medians were corrected for background intensity. The mean of the signal intensity was calculated from quadruplicate detections. For calculating a standard curve, some of the slide wells were treated with pure antigens (as part of the RayBiotech fluorescent antibody array system kit). The concentration (pg/ml) of chemokines was calculated by incorporating the mean intensity for each sample into the standard curve.
Statistical analysis
Results for each sample were expressed as means + − S.E.M. calculated from three independent experiments, and each experiment was composed of three repeats. Differences were analysed using Student's t test, and values of P < 0.05 were considered to be significant.
RESULTS
Models for the interactions between QC and MCPs
We have previously reported the crystal structure of sQC [30] . In the present study, molecular models for interaction between sQC and MCPs were generated, which revealed that the activesite pocket of sQC can accommodate the first five N-terminal residues (Gln-Pro-Asp-Ala-Ile) of MCPs ( Figures 1A and 1B) . The side-chain amide group of the N-terminal glutamine residue of MCPs is able to point to the catalytic Zn 2+ ion of sQC. Moreover, by superimposition of the published MCP-1/CCL2 and MCP-2/CCL8 structures ( Figures 1C and 1D) , we found that the N-terminal pGlu residue of MCP-2/CCL8 has an inward orientation towards the core of the protein and forms a hydrogen bond to Asn 17 , which may stabilize the conformation of the receptor-binding site [31] . In contrast, the uncyclized N-terminus of MCP-1/CCL2 swings outwards. These observations indicate the importance of the N-terminal pGlu residue of MCPs in their structural integrity and receptor-binding activity.
N-terminal pGlu formation in MCPs is catalysed by QC
To confirm whether QC can catalyse the N-terminal pGlu formation, recombinant MCPs (preMCPs) were incubated with QC and the resulting reaction products were analysed by MS. The results from the nanoESI-MS analysis showed that more than 60 % of preMCPs were converted into pMCPs within 2 h, catalysed by QC (Figure 2) . Furthermore, the resulting pMCPs and the residual preMCPs were isolated from the reaction mixture by a gel-filtration HPLC column (see Supplementary Figure S1 in MCP-1 that was proposed to be able to bind the receptor CCR2 is coloured orange [31] . In contrast with the uncyclized and outward N-terminus of MCP-1/CCL2, the cyclized pGlu residue at the N-terminus of MCP-2/CCL8 has an inward orientation towards the core of the protein and forms a hydrogen bond to Asn 17 , which was suggested to stabilize the conformation of the receptor-binding site in MCP molecules. (D) Close-up view of the inward-facing pGlu residue of MCP-2/CCL8 and the hydrogen bonding between the pGlu and Asn 17 in MCP-2/CCL8.
at http://www.BiochemJ.org/bj/442/bj4420403add.htm) and were used to treat cultured monocytes in the following experiments.
pGlu is required for MCP-stimulated monocyte migration
MCPs are well known to be produced by a number of cells, such as epithelial cells, mononuclear leucocytes and monocytes [20] . In rheumatoid arthritis, monocytes in joints play a significant role in MCP production and further immune cell recruitment [32] . Therefore, in the present study, we used monocytes as a model to investigate the role of QCs in inflammation. A cell migration study was conducted in PBDMs. To determine whether PBD150 can inhibit preMCP-induced cell migration, titration of PBD150 was performed ( Figure 3A) . The result revealed the dose-response curves for both preMCP-1 and preMCP-2. Excellent inhibition of the chemotactic activity of monocytes was observed at 10 μM PBD150.
We then compared the effects of preMCPs and pMCPs on the migration of monocytes. We found that the migration activity was substantially higher when the cells were treated with pMCPs compared with those treated with preMCPs ( Figure 3B ). The migration activity of monocytes was significantly induced by the pMCP-1 treatment (CI = 8.02), but was only slightly induced by the preMCP-1 treatment (CI = 3.36) ( Figure 3B, bars 1 and  3) . Similar results were also observed in MCP-2, MCP-3 and MCP-4 ( Figure 3B) . Notably, the weak effect of preMCPs on the migration activity of the cells might be due to the possibility that a portion of preMCPs was converted into pMCPs by the endogenous QC.
We then verified whether QC inhibitor can attenuate the migration activity. We pretreated the cells with PBD150 and found that PBD150 almost completely inhibited the stimulatory effects of preMCPs ( Figure 3B , compare bars 1 and 2, 5 and 6, 9 and 10, and 13 and 14). In contrast, the effect of pMCP-1 on the migration activity was not affected by the PBD150 pretreatment ( Figure 3B , compare bars 3 and 4). As shown in Figure 3(B) , PBD150 pretreatment caused a ∼ 70 % reduction in migration activity by preMCP-1 (bars 1 and 2). Similar effects were also observed for other three isoforms of MCPs ( Figure 3B ).
Knockdown of sQC or isoQC by siRNA reduces monocyte migration
To further verify whether QC is required for MCP-induced migration, we used siRNA to knock down QC expression. As shown in Figure 4(A) , the protein level of sQC was reduced substantially by sQC-specific siRNAs (si-sQC-1) compared with the siRNA control (siC) ( Figure 4A ). Similarly, the protein level of isoQC was significantly reduced by isoQC-specific siRNAs (si-isoQC-1 and si-isoQC-2) compared with the siRNA control (siC). Meanwhile, si-sQC and si-isoQC siRNAs did not alter the protein expression of isoQC and sQC respectively ( Figure 4A ). Protein levels of MCP-1 and MCP-2 were not changed by sQCspecific siRNAs and isoQC-specific siRNAs compared with the siRNA control (siC) ( Figure 4B ).
Migration activity was reduced by approximately half when we compared si-sQC-1 with siC by preMCP-1 or preMCP-2 treatment (reduction in CI from 3.50 to 1.93 and from 3.42 to 1.92 for preMCP-1 and preMCP-2 respectively) ( Figure 4C ). 1.15 μM) . The major peak, as indicated, corresponds to a mass of 8681.0, which is close to the theoretical molecular mass (8679.4) of preMCP-1 (left-hand panel). After incubating preMCP-1 with recombinant QC, the major peak corresponds to a mass of 8664.3, which is close to the theoretical molecular mass (8662.4) of pMCP-1 (right-hand panel). (B) NanoESI-MS analysis of preMCP-2 (1.12 μM). The major peak, as indicated, corresponds to a mass of 8910.6, which is close to the theoretical molecular mass (8909) of preMCP-2 (left-hand panel). After incubating preMCP-2 with recombinant QC, the major peak corresponds to a mass of 8894.9, which is close to the theoretical molecular mass (8892) of pMCP-2 (right-hand panel). (C) NanoESI-MS analysis of preMCP-3 (1.12 μM). The major peak, as indicated, corresponds to a mass of 8952.3, which is close to the theoretical molecular mass (8950.6) of preMCP-3 (left-hand panel). After incubating preMCP-3 with recombinant QC, the major peak corresponds to a mass of 8935.0, which is close to the theoretical molecular mass (8933.6) of pMCP-3 (right-hand panel). (D) NanoESI-MS analysis of preMCP-4 (1.16 μM). The major peak, as indicated, corresponds to a mass of 8595.7, which is close to the theoretical molecular mass (8593.5) of preMCP-4 (left-hand panel). After incubating preMCP-4 with recombinant QC, the major peak corresponds to a mass of 8579.0, which is close to the theoretical molecular mass (8576.5) of pMCP-4 (right-hand panel).
Figure 3 Effects of preMCPs and pMCPs on the migration activity of PBDMs
(A) Migration of PBDMs is inhibited by PBD150. PBDMs (2×10 5 ) were pretreated with 0.1, 1 or 10 μM PBD150 for 2 h, and supernatants were harvested for migration assays and were loaded into the lower chamber in the presence of preMCP-1or preMCP-2 (20 ng/ml). After 2 h, migration of fresh PBDMs to the lower chamber was evaluated. For detailed information, see the Experimental section. The fold cell migration (CI) is derived from the mean FU value of cell migration through the BD FluoroBlok membrane towards a chemoattractant divided by the mean FU value of cell migration in the absence of chemoattractant. The CI value was defined as 1 for cell migration in control medium. The CI value of each sample is shown as the mean + − S.E.M., calculated from three independent migration experiments. *P < 0.05, **P < 0.01. (B) PBD150 inhibits preMCP-but not pMCP-induced cell migration. PBDMs (2×10 5 ) were pretreated with PBD150 (10 μM). After 2 h, supernatants were harvested for migration assays and were loaded into the lower chamber in the presence of preMCPs or pMCPs (20 ng/ml). After a further 2 h, migration of fresh PBDMs was measured. The CI value of each sample is shown as the mean + − S.E.M. calculated from three independent experiments performed in triplicate. *P < 0.05.
Inhibition in migration activity was ∼ 45 % by preMCP-1 and ∼ 44 % by preMCP-2 by using si-sQC-1. Migration activity was also reduced by si-isoQC-1 and si-isoQC-2 ( Figure 4D ). Inhibition was ∼ 67 % triggered by si-isoQC-1 for preMCP-1 and preMCP-2 treatment, whereas inhibition was ∼ 67 % and ∼ 66 % triggered by si-isoQC-2 for preMCP-1 and preMCP-2 respectively.
The role of QC in monocyte migration by LPS treatment
It is well known that LPS can stimulate the expression of MCPs in monocytes [33] . Similar results were also observed in the present study ( Figure 5A , bars 2 and 5). The migration activities of U937 cells and PBDMs were induced by LPStreated conditioned medium ( Figure 5B , bar 3, and Figure 5C , bar 3). Furthermore, inhibition of QC activity by PBD150 significantly suppressed cell migration. When pretreated with 10 μM PBD150, the migration activities of U937 cells and PBDMs were reduced 2.8-fold (reduction in CI from 8.42 to 3.03) and 2.1-fold (reduction in CI from 7.13 to 3.39) respectively ( Figures 5B and 5C ). We also checked whether the amounts of MCP-1 and MCP-2 were affected by PBD150 treatment. As shown in Figure 5 (A), no detectable change in the levels of MCP-1 and MCP-2 were observed. In addition, we also analysed the cytotoxicity of PBD150 in U937 cells and found that no obvious toxicity was observed at PBD150 concentrations lower than 100 μM (see Supplementary Figure S2 at http://www.BiochemJ. org/bj/442/bj4420403add.htm).
Other chemokines induced by LPS were verified using a chemokine array. We found that the levels of ten chemokines, including MCP-3/CCL7, PARC/CCL18, IP-10/CXCL10 and I-TAC/CXCL11, were elevated by LPS treatment (see Supplementary Figure S3 at http://www.BiochemJ.org/bj/ 442/bj4420403add.htm). Pretreatment with PBD150 had no effects on the levels of these chemokines, except for MCP-3, whose level was slightly reduced, probably owing to its autoregulation (Supplementary Figure S3A) . Moreover, we also analysed the effect of PBD150 on the levels of IL8/CXCL8 and TNF-α by ELISA and found that their levels were not affected by PBD150 pretreatment (Supplementary Figures S3F and S3I) .
As a control for cell migration mediated by LPS with its counteracting receptor, Toll-like receptor 4, we treated cells with LTA, a ligand for Toll-like receptor 2, to verify whether LTA induces MCPs and mediates cell migration. Our results show that LTA may induce MCP-1 protein, and this effect was not altered by PBD150 ( Figure 6A ). The other ligand, IFNγ , may induce the MCP-1 protein, and this effect was not affected by PBD150 either ( Figure 6A ). The migration activity induced by LTA (10 μg/ml) and IFNγ (100 ng/ml) was 11.6 and 9.08 respectively, whereas PBD150 (10 μM) can inhibit the migration activity to 5.12 and 5.34 respectively, with P < 0.01 ( Figure 6B ).
To determine whether the migration responses to LPS are entirely attributed to MCPs, we used a CCR2-neutralizing antibody to block the action of MCPs. We found that the anti-CCR2 antibody was able to reduce the migration activity substantially, whereas the IgG-isotype antibody, acting as a negative control, had almost no effect on the migration activity ( Figure 5D ).
QC activity in monocytes is regulated
A previous paper reported that LPS can induce the elevation of QC activity in macrophage cells [9] . In the present study, we treated both U937 cells and PBDMs with 0.25-16 μg/ml LPS for 48 h and found that the QC activities in the cell extracts were significantly increased, from 13.1 units/mg to 23.56 units/mg in U937 cells and from 3.56 units/mg to 16.5 units/mg in PBDMs (1 unit is defined as the amount required to catalyse the cyclization of 1 nmol of substrate per h) (see Supplementary Figure  S4A at http://www.BiochemJ.org/bj/442/bj4420403add.htm). In contrast, QC activities in the cultured medium were only slightly increased (Supplementary Figure S4B) .
We pretreated the cells with PBD150 at a concentration range of 0.001-100 μM and then analysed the QC activity in the cell extract and culture medium. The results showed that the QC activities in cell extract and culture medium were all significantly decreased (Supplementary Figures S4C and S4D) . Notably, the inhibition curves for cell extracts from U937 cells and PBDMs were quite different, indicating that different cell types display distinct sensitivities to PBD150. Moreover, we measured the mRNA and protein levels of sQC and isoQC before and after LPS treatment and found that the levels of sQC and isoQC showed no significant change (see Supplementary Figures S5A-S5C at http://www.BiochemJ.org/bj/442/bj4420403add.htm). In Figure 4 Knockdown of QCs by siRNA reduces monocyte migration U937 cells were infected with lentiviral vector harbouring negative control siRNA (siC), sQC-specific siRNA (si-sQC-a and si-sQC-1) or isoQC-specific siRNA (si-isoQC-1 and si-isoQC-2). GFP-positive cells were sorted using a FACSAria Cell Sorter. Supernatant obtained from a retroviral vector-delivered siRNA to sQC or isoQC cells was collected for migration assays and ELISA assays for MCP-1 and MCP-2 measurement. (A) Protein levels of QCs in si-sQC and si-isoQC knockdown cells were measured by Western blot analysis. Band intensity was determined using Quantity One software (Bio-Rad Laboratories). GAPDH was used as a loading control. The relative expression was revealed as the ratio of sQC to GAPDH, and isoQC to GAPDH, as indicated. The protein level of sQC was efficiently suppressed by si-sQC-1, but not by si-isoQC-1 and si-isoQC-2. The protein level of isoQC was efficiently suppressed by si-isoQC-1 and si-isoQC-2, but not by si-sQC-1 and si-sQC-a. (B) Protein levels of MCP-1 and MCP-2 produced by the above-mentioned siRNA knockdown cells were measured by ELISA. Open and closed bars indicate MCP-1 and MCP-2 respectively. (C and D) Migration activity of si-QC knockdown cells. Supernatant from a retroviral vector-delivered siRNA to sQC (C) or isoQC (D) cells was collected for migration assays and loaded into the lower chamber in the presence of preMCP-1 or preMCP-2 (20 ng/ml). After 2 h, cells that migrated to the lower chamber were evaluated. Cell migration induced by preMCP-1 or preMCP-2 treatment was efficiently reduced upon introduction of si-sQC-1, si-isoQC-1 and si-isoQC-2, compared with siC. Results are means + − S.E.M. for three independent experiments performed in triplicate. *P < 0.05. addition, we also estimated and compared the quantities of sQC and isoQC in the cell extracts of U937 cells and found that the amounts of these two QCs were comparable (Supplementary Figure S5D) .
DISCUSSION
The biological activities of proteins are regulated in numerous ways, such as post-translational modifications including phosphorylation/dephosphorylation, acetylation, prenylation and glycosylation. These post-translational modifications modulate many pathways in cells, thereby affecting numerous important physiological and pathological processes such as cell-cycle progression, growth, differentiation and apoptosis [34] . In the present study, we clarified a poorly understood post-translational modification, namely formation of N-terminal pGlu. pGlu modification has been seen in secretory proteins, including thyrotropin-releasing hormone, luteinizing hormone-releasing hormone and MCPs [6, 35, 36] . The present study explored the role of N-terminal pGlu formation in MCPs. A previous study showed that only a small proportion (approximately 12-15 %) of recombinant MCP-2 overexpressed in E. coli underwent spontaneous pGlu formation [37] . In the present study, we demonstrated that QC can largely convert preMCPs into pMCPs.
Three lines of approaches, including pharmacological inhibition of QC, using siRNA to QC and blocking MCP actions using a neutralizing antibody, were used in the present study; all of these reduced cell migration substantially. These results are summarized in Figure 7 . Collectively, pGlu formation is important for MCPs in stimulating monocyte migration.
It is well known that the N-terminal pGlu residue of proteins can help to stabilize the proper conformation of proteins for binding to their receptors and/or can protect the N-terminus of proteins from exopeptidase degradation [5, 6, 38] . Regarding the four MCPs, pGlu formation was believed to play a critical role for the binding of MCPs to their monocyte cell-surface receptors, which then induced subsequent migratory and chemotactic activities of the cells [6, 23, 24] . The crystal structure of pGlu-containing MCP-2/CCL8 revealed that the N-terminal pGlu is buried, and participates in forming a hydrogen bond and a salt bridge close to the putative receptor-binding site [37] . In contrast, the structures of the N-terminal uncyclized precursors of MCP-1/CCL2, MCP-3/CCL7 and MCP-4/CCL13 showed the protruding and flexible N-termini, which tend to swing away from their receptor-binding site [39] [40] [41] . These studies clearly indicate a critical role of the N-terminal pGlu in both the integrity of the MCP structures and the biological activities of these proteins.
Van Coillie et al. [6] described that pMCP-2 was resistant to degradation by the serine protease CD26/dipeptidyl peptidase
Figure 5 Effects of QC inhibitor on MCP-induced migration upon LPS stimulation
(A) The effects of LPS (4 μg/ml) and PBD150 (10 μM) on the expression levels of MCP-1 and MCP-2 were evaluated by ELISA in U937 cells. The LPS-induced total MCPs, which include the preMCPs and pMCPs, cannot be differentiated by the available antibodies. (B) Migration activity of U937 cells by LPS and PBD150 treatment. U937 cells were pretreated with PBD150 for 2 h and then treated with LPS (4 μg/ml) for 48 h. The conditioned medium was harvested for migration assays and loaded into a lower chamber. After 2 h, fresh U937 cells that migrated to the lower chamber were evaluated. The PBD150 concentrations used were 0.001-100 μM. (C) Migration activity of PBDMs by LPS and PBD150 treatment. Conditioned medium obtained from PBDMs treated with LPS and PBD150 was used as mentioned above. The conditioned medium was harvested for migration assays and loaded into a lower chamber. After 2 h, fresh PBDMs that migrated to the lower chamber were evaluated. The PBD150 concentrations used were 0.1-10 μM. (D) U937 cells were treated with LPS (4 μg/ml) for 48 h, and the conditioned medium was harvested for migration assays and was loaded into the lower chamber. Fresh U937 cells were pretreated with 1 or 10 μg/ml anti-CCR2 neutralizing antibody (CCR2 Abs; E68, Abcam) or an isotype antibody (IgG Abs) for 4 h and, after washing three times, 10 6 cells were loaded into the upper chamber for migration assays. After 2 h, cells that migrated to the lower chamber were evaluated. All results shown are means + − S.E.M. for three independent experiments performed in triplicate. *P < 0.05, **P < 0.01.
IV, but the N-terminal unmodified preMCP-2 was susceptible to degradation, supporting the view that the N-terminus of MCPs is protected from protease degradation. Gong and Clark-Lewis [23] and Clark-Lewis et al. [42] reported that the N-terminallytruncated or acetylated variants of MCP-1/CCL2 could act as antagonists of MCP-1/CCL2 that are able to bind to their receptors without inducing chemotactic activity. Along this line, Proost et al. [24] have identified the endogenous N-terminally-truncated forms of MCP-1/CCL2 and MCP-2/CCL8 from human monocytes. On the basis of these findings, it is conceivable that blocking the QC activity in monocytes may lead to an accumulation of truncated MCPs, which then serve as antagonists for the receptor.
Recently, a Golgi-resident QC (isoQC) was reported [7] , which is widely distributed in various tissues. This enzyme shares catalytic characteristics identical with those of sQC, therefore both sQC and isoQC might contribute to pGlu formation before secretion of the substrates [43] . In the present study, siRNA to isoQC is more prominent in the migration-inhibition experiment, indicating a more important role of isoQC for monocytes. However, a number of factors may also contribute to the regulation of pGlu formation for MCPs. First, the exact amount and differential expression of sQC and isoQC in different cell types remains unclear. Secondly, the compartment of MCPs and sQC/isoQC from protein synthesis to secretion, i.e. the maturation and secretion process of MCPs and sQC/isoQC that may meet each other in the same vesicle, is unclear and must be determined. It is possible that the N-terminal glutamine residue of MCPs is exposed during signal peptide cleavage, which might be accessed by sQC or isoQC in the ER (endoplasmic reticulum), or MCPs can be accessed by sQC after its secretion into the extracellular space. A pGlu-specific antibody and genetic ablation of sQC or isoQC will be helpful in resolving this issue. During the reviewing process of the present paper, Cynis et al. [44] reported the isoQCknockout mouse model and indicated that pGlu formation of MCPs is critical in monocyte migration, which is consistent with our present findings. In their study, isoQC plays a major role in a lung inflammation and peritonitis model. However, ∼ 30-40 % of pMCP-1 was left in isoQC-knockout mice [44] , implying that a complementary role of sQC or auto-pGlu formation of MCP-1/CCL2 may occur in the inflammation.
Unexpectedly, QC activity in cell extracts was elevated after LPS stimulation (Supplementary Figure S4) , whereas the mRNA and protein levels of sQC and isoQC showed no significant alteration (Supplementary Figures S5A-S5C) . A possible explanation for the increased QC activity is post-translational The effect of PBD150 on MCP-induced migration upon LTA and IFNγ stimulation. U937 cells were pretreated or not with PBD150 for 2 h, followed by treatment with LTA (1 μg/ml or 10 μg/ml) for 24 h and IFNγ (10 ng/ml or 100 ng/ml) for 12 h; supernatants were harvested for migration assays and loaded into the lower chamber. After 2 h, fresh U937 cells that migrated to the lower chamber were measured. All results shown are means + − S.E.M. for three independent experiments performed in triplicate. *P < 0.05, **P < 0.01. modification, such as glycosylation or phosphorylation, or other mediators involved in modulating sQC and isoQC activity. The role of these molecules or mechanisms in modulating QC activity, and other pathophysiological states, will probably become more complex and important, and warrants further investigation.
In addition to acute inflammation, tumours also secrete pro-inflammatory cytokines and/or chemokines to recruit inflammatory cells and to stimulate angiogenesis for tumour growth [45] . It has been proposed that MCPs may contribute to tumour angiogenic activities and may be associated with human cancers through cognate receptors, CCR receptors [46] . CCR5 was reported as the main co-receptor to CXCR4, which mediates HIV entry and replication [47] . Truncated MCPs that bind to these co-receptors may block HIV infection or tumour metastasis effectively [48] .
In summary, QC plays an important role in pGlu formation of MCPs, which consequently enhance the activation and migration of monocytes. Furthermore, our results provide new insights into the role of QC in the inflammation process, and we suggest that QC inhibitors may be potential drug candidates for inflammation, HIV infection or tumours. 
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Figure S3 Effects of LPS and PBD150 on the levels of various chemokines and TNF-α
The levels of various chemokines in U937 cells after treatment with LPS and/or PBD150 were evaluated by a chemokine array, and the levels of IL-8/CXCL8 and TNF-α were evaluated by ELISA. The 40 chemokines tested in the chemokine array are listed in the Experimental section of the main paper. Of these chemokines, ten appeared to be up-regulated by LPS: MCP-3/CCL7, PARC/CCL18, MIP-3α/CCL20, GRO/CXCL1, I-TAC/CXCL11 and IP-10/CXCL10 (A, C-E, G and H), and MCP-2/CCL8, MPIF-1/CCL23, CCL28 and CXCL16 (results not shown). The effects of the above six chemokines, and of MCP-4/CCL13 (B), IL8/CXCL8 (F) and TNF-α (I) affected by PBD150 (0.1, 1 and 10 μM) were listed and measured. Of the ten LPS-induced chemokines, the levels of MCP-3/CCL7 could be significantly attenuated (P < 0.05) by the pretreatment of PBD150, whereas MCP-4/CCL13 was not induced by LPS. The effect of MCP-2/CCL8 was measured by the chemokine array and was similar to that determined by ELISA (results not shown). Results are means + − S.E.M. for three independent experiments. *P < 0.05. N.D, not determined. 
